BioPharm Systems Unveils Siebel Clinical Process Reengineering Service to Extend CTMS
BioPharm Systems announced that it is unveiling a new service to help life sciences companies maximize the return on investment for Oracle's Siebel Clinical Trial Management System (CTMS). The new BioPharm Systems Siebel Clinical Process Reengineering service extends the company's existing clinical trial management practice offerings.
BioPharm Systems' Siebel Clinical Process Reengineering service aims to allow sponsors and clinical research organizations to reduce cost, boost productivity, and increase compliance. After an analysis of a company's organizational structure, user roles and task divisions, training materials, standard operating procedures, and other process documentation that involve Siebel Clinical, BioPharm Systems will make sound recommendations for improving efficiencies around the use of their CTMS.
Members of BioPharm Systems' clinical trial management practice have been implementing Siebel Clinical since its inception and have experience in the system itself and in the best practices surrounding its use. The company's pre-configured and enhanced version of Siebel Clinical, ASCEND, was recently presented with the 2011 Innovation Award for Excellence in Technology in Health Sciences from the Oracle Health Sciences User Group. BioPharm Systems also recently received an Oracle PartnerNetwork North America Titan Awards Honorable Mention in the Oracle Accelerate for Midsize Companies category.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.
